

# To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

NCT06756269

---

|            |  |
|------------|--|
| Status     | RECRUITING                             |
| Phase      | Phase 2                                |
| Sponsor    | Shanghai Bovax Biotechnology Co., Ltd. |
| Enrollment | 330 participants                       |

## Key Eligibility Criteria

---

### Inclusion (7)

- Participants aged 9-45
- Participants aged 18-45 who can provide legal identification participants aged 9-17 and their guardian can provide legal identification
- Participants and/or their guardian sign an informed consent form;
- Axillary temperature less than 37.3 °C >14 years old or less than 37.5 °C <14 years old at the time of enrollment
- Be able to comply with study protocol requirements
- ... and 2 more (see full listing online)

### Exclusion (19)

- Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV vaccines during the study period
- Plan to participate other clinical trials during the study period or participated other clinical trials including vaccine or drug and received medication or vaccine within 3 months before enrollment ,
- History of positive HPV testing (including types not covered by the trial vaccine) among the participants aged 18-45 years old;
- History of CIN2/AIS/Cervical Cancer/Pelvic radiation therapy in female participants;
- History of HPV-related external genital diseases (such as genital warts, Vulvar intraepithelial neoplasia, Vaginal intraepithelial neoplasia, Penis/perianal/perineum intraepithelial neoplasia, Penile/perianal/perineal cancer) anal intraepithelial neoplasia and related cancer, or head and neck cancer history of sexually transmitted diseases (including syphilis Gonorrhea, genital chlamydia infection, genital herpes, soft chancre, sexually transmitted lymphogranuloma, inguinal granuloma, etc.);
- ... and 14 more (see full listing online)

## Locations (1 total)

---

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China